DRUG STUDY
DRUG ACTION
GENERIC NAME:
folic acid(vitamin b9)
BRAND NAME:
FA-8
DOSAGE:
0.4-0.8mg P.O daily
before conception
through at least first 4 to
12 weeks of fetal
formation.
For women at high risk,
recommended dosage
is 4mg daily starting up
to 3 months before
conception and through
first 3 months of
pregnancy.
FREQUENCY:
before conception
through at least first 4 to
12 weeks of fetal
formation.
ROUTE:
PER OREM
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
INDICATION
Folic acid, as it is  To prevent neural
biochemically inactive,
is converted to
tetrahydrofolic acid and
methyltetrahydrofolate
by dihydrofolate
reductase (DHFR).
These folic acid
congeners are
transported across cells
by receptor-mediated
endocytosis where they
are needed to maintain
normal erythropoiesis,
synthesize purine and
thymidylate nucleic
acids, interconvert
amino acids, methylate
tRNA, and generate and
use formate. Using
vitamin B12 as a
cofactor, folic acid can
normalize high
homocysteine levels by
remethylation of
homocysteine to
methionine via
methionine synthetase.
SIDE EFFECTS NURSING
INTERVENTION
• Nausea • Explain the needs of
tube defects of taking folic acid
fetus during • Gas or bloating
pregnancy. • Explain the side effects
• Poor appetite that may occur and also
danger signs for
• Trouble sleeping adverse reactions to the
supplement
• Feeling depressed or
overly excited • Assess client history
for any contraindications
• Assess for allergies to
folic acid or any
component found in the
supplement being taken
• Assess drugs already
being taken for any
adverse drug
interactions
• Instruct client not to
drink alcohol during the
duration of folic acid
supplementation
 DRUG STUDY
DRUG ACTION INDICATION SIDE EFFECTS NURSING
INTERVENTION
GENERIC NAME: Acts directly on the Following delivery of Side effects include: Monitor bp, heart rate,
Methylergometrine maleate smooth muscle of the placenta, for routine Nausea uterine response
uterus and increases management of uterine Vomiting frequently, during
BRAND NAME: the tone, rate, and atony, hemorrhage, stomach pain medication
Methergine amplitude of rhythmic and sub involution of diarrhea administration.
contractions through the uterus. leg cramps Notify health care
DOSAGE: binding and the For control of uterine increased sweating professionals if uterine
resultant antagonism hemorrhage in the relaxation becomes

PO
skin rash
of the of the dopamine second stage of labor prolonged or if
headache
D1 receptor. Thus, it following the delivery character of vaginal
induces a rapid and of the anterior dizziness bleeding changes.
ringing in your ears

(Adults)
sustained tetanic shoulder.
uterotonic effect which stuffy nose
shortens the third unpleasant taste in
stage of labor and your mouth

: 200–
reduces blood loss.

400 mcg
(0.4– 0.6
mg) q
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

6– 12 hr
for 2–
7 days.
IM, IV
(Adults)
: 200
mcg (0.2
mg) q
2– 4
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

hr for up
to 5
doses
PO
(Adults)
: 200–
400 mcg
(0.4– 0.6
mg) q
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

6– 12 hr
for 2–
7 days.
IM, IV
(Adults)
: 200
mcg (0.2
mg) q
2– 4
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

hr for up
to 5
doses
PO
(Adults)
: 200–
400 mcg
(0.4– 0.6
mg) q
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

6– 12 hr
for 2–
7 days.
IM, IV
(Adults)
: 200
mcg (0.2
mg) q
2– 4
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

hr for up
to 5
doses
PO
(Adults)
: 200–
400 mcg
(0.4– 0.6
mg) q
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

6– 12 hr
for 2–
7 days.
IM, IV
(Adults)
: 200
mcg (0.2
mg) q
2– 4
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

hr for up
to 5
doses
PO
(Adults)
: 200–
400 mcg
(0.4– 0.6
mg) q
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

6– 12 hr
for 2–
7 days.
IM, IV
(Adults)
: 200
mcg (0.2
mg) q
2– 4
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

hr for up
to 5
doses
PO
(Adults)
: 200–
400 mcg
(0.4– 0.6
mg) q
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

6– 12 hr
for 2–
7 days.
IM, IV
(Adults)
: 200
mcg (0.2
mg) q
2– 4
STUDENT NAME: HADDIEA A. ABDULBAYAN, RM
 DRUG STUDY

hr for up
to 5
doses.
Intramuscularly1 mL, 0.2 mg,
after delivery of the anterior
shoulder

Intravenously1 mL, 0.2 mg,

administered slowly over a
period of no less than 60
seconds

Orally One tablet, 0.2 mg, 3

or 4 times daily in the
puerperium for a maximum of
1 week.

FREQUENCY:
May be repeated as required,
at intervals of 2-4 hours.

ROUTE: IM, IV, PER OREM

STUDENT NAME: HADDIEA A. ABDULBAYAN, RM

 DRUG STUDY
DRUG ACTION INDICATION SIDE EFFECT NURSING
INTERVENTION
Generic Name: Essential component - Iron Deficiency Occasional: Mild, BASELINE ASSESSMENT
Ferrous Sulfate information of Hgb, Anemia transient nausea. ●Assess nutritional status,
myoglobin, enzymes. dietary history.
Brand Name: - Prevention of Iron Rare: Heartburn, ●To prevent mucous
membrane and teeth staining
Femiron Promotes effective Deficiency. anorexia, constipation,
with liquid preparation, use
erythropoiesis and diarrhea. dropper or straw and allow
Dosage: transport, utilization of solution to drop on back of
1 tablet of 325mg oxygen. tongue.

Frequency: INTERVENTION/EVALUATION
once a day ●Monitor serum iron, total iron-
binding capacity, reticulocyte
Route: count, Hgb, ferritin.
Per Orem ●Monitor daily pattern of bowel
activity, stool consistency.
●Assess for clinical
improvement, record relief of
iron deficiency symptoms
(fatigue, irritability, pallor,
paresthesia of extremities,
headache).

PATIENT/FAMILY
TEACHING
•Expect stool color to darken.
•Oral liquid may stain teeth.
•If GI discomfort occurs, take
after meals or with food.
•Do not take within 2 hrs of
other medication or eggs, milk,
tea, coffee, cereal.

STUDENT NAME: HADDIEA A. ABDULBAYAN, RM